A phase 2 trial of orelabrutinib showing promising efficacy and safety in patients with persistent or chronic primary immune thrombocytopenia

Authors:

Published: 0000-00-00

DOI: HTTPS://DOI.ORG/10.1002/ajh.27303

Keywords:

Abstract:

Source: